David A. Weinstein, MD, M.M.Sc.
Following his graduation from Trinity College (CT) and Harvard Medical School, Dr. Weinstein completed a residency, chief residency, and fellowship in pediatric endocrinology at Children’s Hospital Boston. He subsequently obtained a Masters in clinical investigation from Harvard and MIT, and became Director of the Glycogen Storage Disease Program at Children’s Hospital Boston. In 2005, Dr. Weinstein moved to the University of Florida where he directs the Glycogen Storage Disease Program and has been a Full Professor of Pediatrics since 2011. Dr. Weinstein follows the largest cohort of hepatic GSD patients in the world, and he has published over 50 articles and 22 textbook chapters on this topic. He is a former Jan Albrecht Award winner from the American Association for the Study of Liver Diseases, and he served on the Board of Directors for the Association for Glycogen Storage Disease for two terms. Dr. Weinstein remains on the scientific advisory boards for both the US and Spain Associations for GSD.
While patients with glycogen storage disease are now surviving into adulthood, long-term complications remain common, and Dr. Weinstein’s team has focused on elucidating the cause of these complications. Previous studies have revealed the pathophysiology for anemia and renal complications in GSD, and Dr. Weinstein’s lab continues to investigate complications in GSD I including hepatocellular carcinoma, hepatic adenomas, and athersclerosis. Curing the glycogen storage diseases remains the ultimate goal. Dr. Weinstein’s laboratory is working on ways to cure the disease through gene therapy or replacement of glucose-6-phosphatase activity. Stem cell therapy is presently being attempted in the mice with GSD type Ia, and gene therapy is being performed in the naturally occurring canine model of this disease.